WASHINGTON, June 9 /PRNewswire/ -- Gentag, Inc. and MacroArray Technologies, LLC have entered into a development program to design a wireless immunoassay incorporating Gentag's cell phone communication technology and MacroArray's urine diagnostic test for prostate cancer.
One in six males are at risk of developing prostate cancer, but unfortunately not all men are being tested. In order to simplify and expand the use of low cost wireless diagnostic assays for early cancer detection, Gentag, Inc. and MacroArray Technologies have teamed to develop a new wireless test platform that will incorporate Gentag's cell phone-sensor technology with MacroArray's proteomics discovery technology to create a series of new, patient friendly, disposable, wireless diagnostic tests. The first of these will be a test for prostate cancer based on MacroArray's proprietary reagents.
Similar to the currently available pregnancy strip test, men will place a urine sample on the test strip that incorporates an imbedded wireless sensor tag. The antibodies in the strip test will react with the antigens in the urine, the resulting data will be sensed by the imbedded electronic tag and communicated to a cell phone or PDA that will process the data and transmit the results to the attending physician.
During the past year, approximately 60 million PSA tests were performed worldwide and over 200,000 men were diagnosed with prostate cancer. Nearly 35,000 will die each year from the disease. It is hoped that the availability of a simple low cost urine-based test will increase the number of men who evaluate their prostate health on a regular basis.
"The proprietary technology from Gentag combined with MacroArray's
biomarkers will provide a significant level of exclusivity in this market,"
commented Dr. John Peeters, CEO of Gentag. "The combination of our two
companies will dramatically expand the utility of our diagnostic tests,"
commented Mr. Mike Wassil, CEO of Macr
|SOURCE Gentag, Inc.|
Copyright©2008 PR Newswire.
All rights reserved